Beyond medicines: strengthening diagnosis and treatment of lymphoma in Ukraine

Partnership objectives

Make lab and imaging test for diagnosis of lymphoma more affordable for patients in Ukraine

Takeda's programme subsidises the cost of diagnostic tests for patients who cannot afford them. Takeda's programme subsidises the cost of diagnostic tests for patients who cannot afford them. Copyright Takeda

What are the health needs and challenges?

The CD30 and PET / CT scans needed for diagnosis of lymphoma are unaffordable for some patients in Ukraine.

Description of partnership activities and how they address needs and challenges

This programme subsidises the cost of diagnostic tests for patients who cannot afford them, and also seeks to strengthen the treatment of lymphoma by providing medical service liaison to healthcare professionals (delivered by third parties National Cancer Institute and GHS Group).

This programme brings Takeda together with the National Cancer Institute of Health Ukraine and CSD Health Care Clinic (in Kiev and 20 regional centres), the National Hematology Institute in Lvov, and the Cherkasky Onco Dispenser in Cherkasky.

Summary of impact and forward looking information

The programme aims to support 30 – 35 patients by end of March 2017, and approximately 100 patients overall.

Partnership information

Company(ies) Takeda

Partner(s) Cherkasky Onco Dispenser, CSD Health Care Clinic, National Cancer Institute of Health Ukraine, National Hematology Institute of Ukraine

Type of Partner(s) Academia / Hospitals

Therapeutic Focus Non-Communicable Diseases

Disease(s) Cancer

Program Type(s) Health System Infrastructure - Outreach & Medical Services

Region(s) Europe & Central Asia

Number of Countries 1

Country(ies) Ukraine

Start Date 2016

Anticipated completion date Ongoing